Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. by Garg, Manoj et al.
UCLA
UCLA Previously Published Works
Title
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro 


















eScholarship.org Powered by the California Digital Library
University of California
1SCIeNTIfIC RepoRtS | 7: 9749  | DOI:10.1038/s41598-017-10325-x
www.nature.com/scientificreports
Selinexor (KPT-330) has antitumor 
activity against anaplastic thyroid 
carcinoma in vitro and in vivo and 
enhances sensitivity to doxorubicin
Manoj Garg1,2, Deepika Kanojia1, Anand Mayakonda1, Trivadi S Ganesan2, Bindhya 
Sadhanandhan2, Sidhanth Suresh2, Sneha S.2, Rohit P. Nagare2, Jonathan W. Said3, Ngan B. 
Doan3, Ling-Wen Ding  1, Erkan Baloglu4, Sharon Shacham4, Michael Kauffman4 & H. Phillip 
Koeffler  1,5
Anaplastic thyroid carcinoma (ATC) is one of the most lethal malignancies having no effective 
treatment. Exportin-1 (XPO1) is the key mediator of nuclear export of many tumor suppressor proteins 
and is overexpressed in human cancers. In this study, we examined the therapeutic potential of 
selinexor (XPO1 inhibitor) against human ATC cells both in vitro and in vivo. Here, we showed that XPO1 
is robustly expressed in primary ATC samples and human ATC cell lines. Silencing of XPO1 by either 
shRNA or selinexor significantly reduced cellular growth and induced cell cycle arrest, apoptosis of 
ATC cells by altering the protein expression of cancer-related genes. Moreover, selinexor significantly 
inhibited tumor growth of ATC xenografts. Microarray analysis showed enrichment of DNA replication, 
cell cycle, cell cycle checkpoint and TNF pathways in selinexor treated ATC cells. Importantly, selinexor 
decreased AXL and GAS6 levels in CAL62 and HTH83 cells and suppressed the phosphorylation of 
downstream targets of AXL signaling such as AKT and P70S6K. Finally, a combination of selinexor with 
doxorubicin demonstrated a synergistic decrease in the cellular proliferation of several ATC cells. These 
results provide a rationale for investigating the efficacy of combining selinexor and doxorubicin therapy 
to improve the outcome of ATC patients.
Thyroid cancer is the most common endocrine malignancy and it is increasing worldwide (approximately 5 to 6% 
increase every year)1, 2. The majority of patients with thyroid cancer has well-differentiated tumors and usually is 
cured by surgical resection. Anaplastic thyroid carcinomas (ATCs) are rare, accounting for less than 2% of all the 
thyroid malignancies. ATC is extremely aggressive with a very low cure rate, and the average 5-year survival is 
less than 10% with a median survival of 3 to 5 months3, 4. Multimodal treatments including surgery, radiotherapy 
and conventional chemotherapeutic agents such doxorubicin have all been used but the clinical outcome remains 
dismal5. Currently, no effective treatment options are available in the clinics for patients with ATC. Therefore, 
development of small molecule targeted therapy will be an exciting strategy for treatment of ATC.
Exportin-1/chromosome region maintenance 1 (XPO1/CRM1) is the best-characterized nuclear export 
receptor, involved in the transport of more than 220 proteins as well as selected RNAs from the nucleus to the 
cytoplasm. XPO1 recognizes the leucine-rich nuclear export signal (NES) on proteins6–8 and is an exclusive 
nuclear exporter of several tumor suppressors and growth regulatory proteins such as p21, p53, p73, CDKN1A, 
RB, BRCA1, FOXO, APC, NPM1 and STAT39–13. Overexpression of XPO1 in cancers can lead to an imbalance of 
these proteins in the cytosolic compartment resulting in either inactivation of the tumor suppressor or an excess 
of anti-apoptotic activity (oncoprotein). Overexpression of XPO1 has been reported in leukemia14, lung cancer15, 
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esophageal squamous cell carcinoma16, sarcoma17, 18, hepatocellular carcinoma19, melanoma20 as well as multiple 
myeloma21. High expression of XPO1 has been positively associated with a poor prognosis and short survival 
in selected malignancies14, 22–25. A preliminary analysis of in silico data suggests that ATC has high XPO1 levels. 
Therefore, we hypothesized that the blockade of XPO1 by using XPO1 inhibitors may have potent activity against 
this cancer. Leptomycin B (LMB) is the first natural XPO1 inhibitor which possesses strong anticancer proper-
ties,26, 27 but its toxicity prevented it from being clinically useful28. In contrast, selinexor (KPT-330; Karyopharm 
Therapeutics, Newton, MA, USA) is a first-in-class, oral selective inhibitor of XPO1 resulting in blockade of 
nuclear export. This compound selectively binds to the Cys528 of XPO1, thereby inhibiting XPO1 binding to the 
NES domains of its cargo protein. Phase I trials have indicated that selinexor is well tolerated and has a favorable 
outcome in patients with acute myeloid leukemia29, 30. To our knowledge, no clinical trials have determined the 
effectiveness of selinexor against ATC. Therefore, we have examined the role of this drug in ATC to determine 
whether it possesses significant antitumor activity against ATC and provide rationale for conducting clinical tri-
als of selinexor in patients with ATC. In the present study, we observed that the drug inhibited cell proliferation 
including clonogenic growth and induced apoptosis of ATC cells in vitro as well as growth of ATC xenografts. 
Moreover, selinexor, when combined with doxorubicin showed increased anticancer activity.
Results
XPO1 expression in human ATC patient samples and cell lines and effect of silencing of XPO1 
in ATC cells. We evaluated the expression of endogenous XPO1 protein in thyroid patient samples using 
immunohistochemistry on 39 papillary, 8 follicular, 10 anaplastic and 10 benign thyroid tissue sections using 
XPO1 antibodies. Nuclear staining of XPO1 was observed in 77% (30 of 39) of papillary, 75% (6 of 8) of follicular 
and 90% (10 of 9) of anaplastic thyroid carcinoma. In contrast, either very weak or no positive immunoreactivity 
of XPO1 was observed in benign thyroid tissues (Fig. 1A). Further, protein expression of XPO1 was examined 
in a panel of ATC cell lines (OGK-M, HTH83, CAL62, T238, SW1736, HTH7, HTH74, C643 and ATC351); and 
Figure 1. Endogenous expression of XPO1 in human ATC samples and cell lines, and effect of silencing of 
XPO1 in ATC cells. (A) Immunohistochemical analysis for detection of endogenous expression of XPO1 
protein in thyroid tumors and benign thyroid tissues. Representative photographs showing nuclear staining 
(brown color) of XPO1 in different histological subtypes of thyroid carcinoma: papillary, follicular, ATC and 
benign thyroid (low or no reactivity) (original magnification, ×200; objective ×20). (B) Western blot analysis 
of ATC cell lines verified that the XPO1 antibody specifically recognizes a band of 123 kDa, corresponding 
to the size of XPO1 protein. (C) Indirect immunofluorescence assay showing nuclear localization of XPO1 
protein in fixed/permeabilized ATC cell lines; DAPI stains nuclei. (D) ATC cells were transduced with 
either XPO1 shRNA or scrambled shRNA. XPO1 knockdown was confirmed in HTH83 and CAL62 cells by 
western blotting. GAPDH antibody was used to assure equal loading of lysates. Original and full-length blots 
are included in the Supplementary Information. XPO1 silencing resulted in decreased cell proliferation of 
HTH83 and CAL62 as measured using MTT assay. Results represent mean ± SD; n = 4. *P ≤ 0.01; **p ≤ 0.001; 
***p ≤ 0.0001(Student’s t-test).
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each had strong XPO1 protein expression (Fig. 1B). Indirect immunofluorescence analysis showed strong nuclear 
localization of XPO1 protein in fixed and permeabilized ATC cells (HTH83, CLA62, T238 and OGK-M) (Fig. 1C, 
Supplementary Figure 1A). To determine the potential role of XPO1 in ATC, endogenous levels of XPO1 were 
silenced in HTH83, CAL62, OGK-M and T238 cells using shRNA targeting to XPO1. XPO1 shRNA showed 
70–90% inhibition of XPO1 in these ATC cell lines both at the mRNA (Supplementary Figure 1B) and protein 
levels (Fig. 1D, Supplementary Figure 1C). Silencing of XPO1 resulted in a significant decrease in cell growth of 
ATC cells in liquid culture compared to scramble shRNA (Fig. 1D, Supplementary Figure 1D).
Selinexor significantly suppressed cellular proliferation and clonogenic growth of human ATC 
cells. Next, we examined whether selinexor could inhibit XPO1 protein expression in ATC cells in vitro. 
OGK-M, HTH83, CAL62 and T238 cells were cultured with increasing doses of selinexor (0–1000 nM) for 24 h. 
The small molecule inhibitor in a dose-dependent manner inhibited XPO1 protein levels in all four cell lines 
(Fig. 2A), but the drug had no significant effect on XPO1 mRNA levels (Supplementary Figure 2A). Selinexor in 
a dose-dependent manner potently inhibited the growth of a panel of ATC cell lines with IC50 values between 
150–500 nM in liquid culture (Fig. 2B). In contrast, the drug had no significant anti-proliferative effect against 
normal rat thyroid cells (FRTL5; Fischer rat thyroid cells) (Supplementary Figure 2B). Furthermore, selinexor sig-
nificantly decreased the clonogenic growth of OGK-M, HTH83, CAL-62 and T238) in a dose-dependent manner 
(Fig. 2C and D).
XPO1 inhibition induced cell cycle arrest and apoptosis of ATC cell lines in vitro. To determine 
whether inhibition of cell growth was due to an alteration in the cell cycle, we analyzed cell cycle distribution 
of ATC cells either exposed to various concentrations (0–1000 nM, 48 h) of selinexor or XPO1 was silenced by 
transfection with XPO1 shRNA. XPO1 inhibition significantly increased G1 phase and decreased the S and G2/M 
Figure 2. Selinexor significantly suppressed cellular growth and clonogenic ability of human ATC cells in vitro. 
(A) OGK-M, HTH83, CAL62 and T238 cells were cultured with increasing concentrations of selinexor (0–
1,000 nM) for 24 h. Whole-cell lysates were prepared, and XPO1 protein expression was analyzed using western 
blot analysis. GAPDH was used as an internal control. Cell viability of eight human ATC cell lines. Original 
and full-length blots are included in the Supplementary Information. (B) Cells were treated with selinexor at 
indicated concentrations for 72 h, and growth inhibition was measured by MTT assay. Results are expressed 
as mean value ± SD; n = 4. (C and D) Representative photomicrograph displayed that selinexor treatment 
decreased clonogenic growth. ATC cells were exposed to indicated concentrations of selinexor for 48 h; cells 
were washed with drug-free medium and allowed to form colonies for 2 weeks followed by crystal violet 
staining and quantification. Data represent mean ± SD of four independent experiments done in triplicates. 
*p ≤ 0.01; **p ≤ 0.001; ***p ≤ 0.0001(Student’s t-test).
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phases in ATC cells (Fig. 3A). Of note, selinexor treatment resulted in cell cycle arrest in a dose-dependent man-
ner (Fig. 3B, Supplementary Figure 3A). Flow cytometric analysis of OGK-M, HTH83, CAL62 and T238 cells 
after propidium iodide and annexin V staining showed a marked dose-dependent increase in the percentage of 
apoptotic cells (PIhigh/AVhigh) after culture with selinexor (0–1000 nM, 48 h) (Fig. 3C, Supplementary Figure 3B). 
Further, we observed that selinexor altered the expression of its known cargo proteins (e.g., p53, p27 and p21), 
as well as indirect targets including cyclin B1, cyclin D1 in the ATC cell lines (Fig. 3D). Selinexor treatment 
(1000 nM, 24 h) also increased cleaved PARP, cleaved caspase-9 and cleaved caspase-3 in ATC cells (Fig. 3D). 
Cleavage of PARP [poly (ADP-ribose) polymerase is one of the hallmarks of apoptosis and caspase activation. 
This was associated with a decrease in the protein levels of anti-apoptotic proteins such as MCL1 and C-Myc 
(Fig. 3D). Moreover, we evaluated the dose-dependent effect of selinexor on the protein expression of a few 
important genes in CAL62 cells (Supplementary Figure 3C).
Selinexor inhibits ATC growth in vivo. The anti-proliferative potential of selinexor was tested in vivo 
against CAL62 human ATC xenografts growing in NSG mice (described in more detail in Material and Method 
Section). When xenograft tumors approached approximately 100 mm3 in volume, mice started to receive either 
selinexor (10 mg/kg dissolved in 100 μl of vehicle administered orally) or 100 μl vehicle alone (3 times per week 
for 4 weeks). Selinexor significantly reduced mean tumor volumes and weights compared to xenograft tumors in 
control mice receiving vehicle (Fig. 4A and B). Western blot analysis of tumor lysates showed that proteins levels 
of cyclin B1 and C-Myc were reduced in tumors obtained from selinexor-treated mice as compared to those from 
vehicle control mice (Fig. 4C). Immunostaining of these dissected tumors displayed the significantly lower num-
ber of XPO1, Ki-67 (cell proliferation marker), and CD31 (blood vessels) positive cells in selinexor-treated mice 
compared to vehicle-treated mice (Fig. 4D and E). Moreover, we observed an increase in the Tunel-positive cells 
(increased apoptosis) in selinexor treated group (Fig. 4D and E). Importantly, selinexor-treated mice maintained 
normal activity, did not lose weight and had comparable levels of total white blood cells, neutrophils, haemat-
ocrit, platelet counts, serum levels of albumin, aspartate aminotransferase, alanine transaminase and creatinine 
compared to the vehicle group (Supplementary Table 2). Taken together, our findings provide a rationale for a 
therapeutic trial of selinexor for the treatment of ATC patients.
Figure 3. Inhibition of XPO1 induced cell cycle arrest and apoptosis of ATC cells in a dose-dependent manner. 
(A) Silencing of XPO1 in ATC cells resulted in an increased in G1 phase. (B) OGK-M, HTH83, CAL62, and 
T238 cells were treatment with either different concentrations of selinexor (0–1,000 nM) or diluent control 
(DMSO), stained with propidium iodide (PI) and analyzed by flow cytometric analysis. Histogram showed 
the proportion of cells in different phases of cell cycle. Data are presented as the mean of three independent 
experiments. (C) ATC cells were treated with selinexor at indicated concentrations for 24 h, stained with 
annexin V-FITC and PI, and subjected to flow cytometric analysis to evaluate the ability of selinexor to induce 
apoptosis. Histograms represent the percentage of apoptotic cells. Data are presented as mean ± SD of three 
independent experiments. *p ≤ 0.01; **p ≤ 0.001; ***p ≤ 0.0001for selinexor vs. controls. (D) OGK-M, 
HTH83, CAL62 and T238 cells were treated with either selinexor (1,000 nM) or DMSO for 24 h. Lysates were 
analyzed by western blot analysis for the indicated cell cycle and apoptosis proteins (GAPDH, internal loading 
control). Original and full-length blots are included in the Supplementary Information.
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Effect of selinexor on gene expression profiling of ATC cells. To study global transcriptome 
changes resulting from inhibition of XPO1, gene expression profiling of OGK-M and HTH83 cells after 
12 hours exposure to selinexor or DMSO was performed using microarray. Gene expression analysis found that 
2491 (FDR < 0.05) genes were differentially expressed upon selinexor treatment across 2 cell lines compared 
to their DMSO group (Fig. 5A). Gene set enrichment analysis (GSEA) showed significant negative enrichment 
in the cell cycle, Aurora kinase pathways and positive enrichment of tumor necrosis factor (TNF) pathway 
(Fig. 5B–E). Further, we analyzed expression of cell cycle genes using publicly available microarray database 
GSE9115. We found that ATC tumor samples had higher expression of cell cycle genes than normal thyroid 
samples31 (Supplementary Figure 4). Reliability of the microarray data was further verified using quantitative 
RT-PCR for 12 randomly selected genes. Expression levels of CCNB1, CCNB2, AURKA, AURKB, AXL, MET 
were significantly downregulated, whereas mRNA levels of TNF, IL-6, CASP3, SMAD7, KLF6 were significantly 
upregulated in selinexor treated HTH83 cells compared to vehicle (Fig. 5F). These results were consistent with 
the microarray data. Taken together, these results showed that selinexor have a moderate effect on cell cycle 
and DNA replication of ATC cells.
Selinexor suppresses AXL signaling in ATC cells. TYRO3 and AXL receptor tyrosine kinases and their 
ligand GAS6 are expressed in several types of the tumor including ATC, and AXL signaling has a key role in cell 
proliferation, migration, invasion, adhesion and survival32–34. Our microarray data showed that AXL and GAS6 
were down-regulated in selinexor treated cells and was confirmed at the mRNA level in ATC cells (Fig. 5F). We, 
therefore, chose to examine whether selinexor inhibits protein levels of AXL in ATC cells. Interestingly, we found 
that selinexor treatment not only suppressed AXL protein levels but also resulted in attenuation of the PI3K path-
way (phosphorylation of AKT and p70S6 kinase) in ATC cell lines (Fig. 6A).
Figure 4. Selinexor inhibits ATC growth in vivo. (A) Immunodeficient mice received ATC cells (CAL62) 
subcutaneously. One week after implantation, mice began to receive either oral selinexor (10 mg/kg, 3 times per 
week for 4 weeks) or vehicle alone. Selinexor treatment significantly suppressed tumor volumes (mean ± SD 
of 6 tumors). *P ≤ 0.01; **P ≤ 0.001; ***p ≤ 0.0001(Student’s t-test). (B) Representative photograph showing 
decreased tumor growth in selinexor treated group compared to vehicle treated group (n = 6 for each group). 
Scale in cm. (Lower panel) Tumor weights from selinexor and vehicle treated groups (mean ± SD of 6 tumors, 
P = 0.000022). (C) At the end of the experiment, whole cell lysates (protein) were prepared from tumors 
resected from selinexor-treated and vehicle-treated mice and subjected to western blotting with indicated 
antibodies. (D and E) Tumor sections were subjected to immunohistochemical analysis. Tumors section from 
the selinexor-treated group showed weak staining for XPO1 (exportin 1), cell proliferation marker (Ki-67) 
and blood vessel marker (CD31) and strong staining for Tunel (a marker of apoptosis) as compared to vehicle-
treated group original magnification, ×200; objective ×20). Columns (on the right) represent mean ± SD of 
three independent tumors. **P ≤ 0.001; ***p ≤ 0.0001 (Student’s t-test).
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Selinexor effectively enhances growth arrest of ATC cells in combination with doxoru-
bicin. Next, we examined whether selinexor could enhance the effect of the chemotherapeutic agents currently 
used to treat ATC. Doxorubicin and paclitaxel are FDA approved drugs for the treatment of ATC patients in the 
clinic5 and therefore a combination of these drugs with selinexor are of particular interest in ATC. In agreement 
with the prior study, we found doxorubicin had a similar inhibitory effect on HTH83, CAL62 SW176, ATC351 
cell lines, with an IC50 about 100 to 200 nM (Fig. 6B and C, Supplementary Figure 5B and E). Notably, we 
observed that combination of selinexor and doxorubicin produced synergistic growth inhibitory activity against 
HTH83, CAL62, SW1736 and ATC351 cells (Fig. 6B–F Supplementary Figure 5A–F). The combination effect is 
more effective in SW1736 and ATC351 cells compared to HTH83 and SW1736 cells. Overall, our results indicate 
that combination of selinexor and doxorubicin might be a potential therapeutic option for targeting ATC. This 
combination warrants further preclinical and clinical development against ATC.
Discussion
ATC is a devastating malignancy which is extremely aggressive and resistant to available chemotherapy2, 5, 35, 36. 
Targeted therapies against proteins which are altered in ATC may hold the key to designing effective treatment 
for this fatal malignancy. The nucleo-cytoplasmic transport of proteins is crucial for maintaining normal cellular 
functions. The process relies on the exportins. XPO1 transports a large number proteins and RNAs across the 
nuclear envelope37. Increased expression of XPO1 occurs with the progression of several types of cancers and 
therefore is an attractive protein for targeted molecular therapy in ATC.
To the best of our knowledge, the present study is the first to verify overexpression of XPO1 protein in human 
ATC samples and cell lines compared to benign thyroid diseases. Immunofluorescence data also support that 
XPO1 is robustly expressed in the nucleus of the ATC cell lines. Further, knockdown of XPO1 suppressed the 
cellular proliferation of several ATC cell lines in liquid culture. Taken together, these data suggest that overexpres-
sion of XPO1 may have a potential role in the pathogenesis of ATC. Recently, several studies showed that Selective 
Inhibitor of Nuclear Export (SINE) compounds have anti-tumor activities with acceptable toxicities15, 17–19, 38. 
Selinexor is an orally available advanced selective inhibitor of XPO1 and is currently being investigated in phase 
I/II clinical trials in patients with advanced solid tumors and hematologic malignancies30, 39. Selinexor treatment 
leads to growth inhibition in liquid culture and markedly suppressed clonogenic ability, as well as decreased 
tumor growth in ATC xenograft model15, 19, 20. Flow cytometric analysis demonstrated that selinexor treatment 
induced cell-cycle arrest and apoptosis in several ATC cells in vitro. Selinexor treatment markedly altered protein 
Figure 5. Effect of selinexor on gene expression profiling of ATC cells. (A) Volcano plot shows differentially 
expressed genes for OGK-M cells treated with either vehicle (DMSO) or 1,000 nM selinexor for 12 h. Red and 
green dots represent up-regulated and down-regulated genes, respectively. Grey dots represented no change. 
(B–E) Gene set enrichment analysis showed negative enrichment of DNA replication, cell cycle, cell cycle 
checkpoint and positive enrichment of TNF (tumor necrotic factor) target pathway. (F) qRT-PCR validation of 
12 selected genes identified as differentially expressed by microarray. Expression of each gene was normalized to 
GAPDH as a reference (control value converted to 1). Figures are representative of 3 replicates. Data represent 
mean ± SD, n = 3. **p ≤ 0.001, ***p ≤ 0.0001. NES indicates normalized enrichment score; and q = false 
discovery rate.
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expression related to cell cycle arrest through upregulation of p53 and p27, and downregulation of cyclin B1, 
cyclin D1 as well as apoptosis-related proteins including upregulation of cleaved caspase 3, cleaved PARP and 
cleaved caspase 9 as well as annexin V positive staining in ATC cells in vitro. Most importantly, selinexor treat-
ment (10 mg/kg, three times per week) leads to inhibition of tumor growth in ATC xenografts, which was asso-
ciated with their decreased proliferation (Ki-67), blood vessel formation (CD31) and increased apoptosis (Tunel 
staining). These observations were consistent with our in vitro findings and also similar to previously published 
reports concerning the effect of selinexor on other malignancies15, 19, 40, 41.
Our microarray analysis also showed that selinexor significantly enriched for pathways related to DNA rep-
lication, cell cycle, cell cycle checkpoint and TNF upon treatment of OGK-M ATC cells with selinexor. Taken 
together, the data suggested that selinexor has a profound effect on the expression of genes involved in cellular 
growth, DNA replication, cell cycle and apoptosis of ATC cells. The transcription factor C-Myc and the tyrosine 
kinase receptor C-Met were highly expressed in ATC and play a vital role in their progression42, 43. Even though 
neither C-Myc nor C-Met are direct XPO1 target proteins, but selinexor indirectly reduced levels of C-Myc and 
C-met proteins. Of note, previous studies of multiple myeloma and hepatocellular carcinoma also observed a 
reduction in the C-Myc and C-Met levels following Selective Inhibitor of Nuclear Export (SINE) treatment of 
these cells19, 21, 44.
Previous studies showed that AXL/TYRO3 and GAS6 play a critical role in ATC progression and survival32. 
Our microarray, qRT-PCR and western blot data verified that selinexor treatment suppressed AXL expression in 
ATC cells. Moreover, we observed that selinexor treatment leads to decreased phosphorylation of downstream 
targets of AXL signaling such as AKT and P70S6K. How selinexor suppresses AXL signaling requires further 
investigation. Moreover, our results demonstrated that the combination of selinexor with doxorubicin synergis-
tically enhanced the anti-proliferative activity of selinexor. This observation is consistent with earlier studies in 
other human malignancies45. Recently, phase I/II clinical trials of selinexor in combination with doxorubicin are 
ongoing for several malignancies.
In summary, our studies showed for the first time that selinexor either alone or in combination with doxoru-
bicin may be effective in the treatment of ATC patients. These studies identify the opportunities for future clinical 
trials for ATC patients.
Materials and Methods
Cell culture. Human ATC cell lines: T238 and CAL62 were kind gifts from L. Roque (Instituto Português de 
Oncologia, Lisboa, Portugal) and Dr. J. Gioanni (Centre Antoine-Lacassagne, Nice, France), respectively. OGK-M 
Figure 6. Selinexor suppressed AXL signaling, and the drug effectively enhanced growth arrest of ATC cells 
in combination with doxorubicin. (A) HTH83 and CAL62 cells were cultured with either selinexor (1,000 nM) 
or diluent control (DMSO) for 24 h, and the whole-cell lysate was subjected to western blot analysis for AXL, 
p-AKT, total AKT, p-P70S6K and total P70S6K. (B and C) Proliferation study of the combination of selinexor 
with doxorubicin. Data represent means ± s.d.; n = 3. (D–F) Combinational growth inhibition of selinexor 
and doxorubicin on CAL62 and HTH83 cells displayed as CI. CI defines the interaction between selinexor and 
doxorubicin as plotted against a fraction of cell viability. CI < 1, CI = 1 and CI > 1 represent synergism, additive, 
and antagonism of the two compounds, respectively.
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cells were established in H. Phillip Koeffler laboratory46. HTH83, SW1736, C643, HTH7 and HTH74 were gen-
erously obtained from Dr. K. Ain (University of Kentucky, Lexington, KY) with permission from Dr. Nils-Erik 
Heldin (University of Uppsala, Sweden). All cell lines were cultured and maintained in RPMI1640 containing 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA) at 37 °C in a humidified 
atmosphere with 5% CO2. FRTL5 cells (Fischer rat thyroid cells) were maintained in Ham’s F12K medium, 5% 
FBS, 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA), 2 mm l-glutamine, 5 μg/ml insulin, 5 μg/ml trans-
ferrin, 10 nM hydrocortisone, 10 ng/ml somatostatin and 1 mU/ml thyroid stimulating hormone (TSH). STR 
profiling of our cell lines was done using the Genetic Resources Core Facility, UCLA, Los Angeles, CA; profiles 
matched to published STR profiles of ATC cell lines (Table 1)46.
Reagent and antibodies. Selinexor (KPT-330) and Pluronic F-68 were obtained from Karyopharm 
Therapeutics (Newton, MA, USA). For in vitro administration, selinexor was dissolved in dimethyl sulfoxide 
(Sigma-Aldrich) to a concentration of 20 mM/L. For in vivo administration, selinexor was dissolved in 0.6% w/v 
aqueous Pluronic F-68 (Karyopharm Therapeutics, Newton, MA, USA). Antibodies to XPO1/CRM1 (H300), 
C-Myc, p27 (C-19), p53 (DO-1), Bax (N20), cyclin D1 (A-12) were from Santa Cruz Biotechnologies (Dallas, TX, 
USA). Antibodies against p21, MCL1, cleaved PARP, cleaved caspase-9, cleaved caspase-3, Aurora-B, AXL, total 
AKT, p-AKT, total P70S6K, p-P70S6K and GAPDH were purchased from Cell Signaling Technology (Danvers, 
MA, USA). Antibody against β-actin was from Sigma-Aldrich.
Immunohistochemistry (IHC). IHC was performed by standard procedures as described previousely46–48. 
Briefly, tumor tissues were fixed in formalin, embedded in paraffin and cut into 4 μm thick sections. Endogenous 
peroxidase activity was blocked using 3% hydrogen peroxide (H2O2), and antigen retrieval was carried out in cit-
rate buffer. Sections were blocked using 3% normal goat serum at room temperature for 40 minutes and incubated 
with primary antibodies against XPO1, CD31, Ki-67 and also for Tunel assay. Immunostaining was assessed by 
counting >500 cells from 5 randomly selected fields of each section using a microscope (Olympus, Tokyo, Japan) 
at ×200 magnification as described previously46, 48.
Western blot analysis. Cell lysates were prepared using M-PER Mammalian protein extraction reagent 
(Thermo Scientific, Rockford, USA) containing 1X protease cocktail inhibitor (Roche). Western blots were per-
formed as described previously47, 49.
cDNA synthesis and quantitative real-time PCR (qRT-PCR). Total RNA was isolated from ATC cell 
lines (CAL62, HTH83 and OGK-M) using the RNeasy mini kit (Qiagen GmbH, Hilden, Germany) according to 
manufacturer’s protocol. 1 ug of total RNA was used for complementary DNA (cDNA) synthesis using cDNA syn-
thesis kit (Life Technologies Inc., Gaithersburg, MA, USA). qRT-PCR was performed using KAPA SYBR master 
mix (Kapa-Biosystems, USA) in an ABI 7500 Fast real-time PCR system (Applied Biosystems, USA). The primers 
used for qRT-PCR for selected genes are shown in Supplementary Table 1.
Indirect immunofluorescence assay. XPO1 protein expression was confirmed in OGK-M, HTH83, 
CAL62 and T238 cells using immunofluorescence as described earlier16. Briefly, cells were fixed with 4% paraform-
aldehyde in PBS pH 7.4 for 10 minutes, washed three times with PBS and incubated with rabbit polyclonal XPO1 
antibody (1:500 dilution) at room temperature for 1 h. Cells were washed and incubated with secondary anti-
body anti-rabbit IgG conjugated with Alexa Fluor 488 (Life Technologies, USA). 4′,6-diamidino-2-phenylindole 
(DAPI; Sigma-Aldrich, St. Louis, MO) was used to stain the nucleus of the cells. The slides were finally washed 
and mounted in mounting medium (Sigma-Aldrich, St. Louis, MO), and images were captured using Nikon 
microscope (Nikon, Fukok, Japan).
Short hairpin RNA (shRNA) interference. To obtained XPO1 knockdown in HTH83, OGKM, CAL62 
and T238 cells, human XPO1 shRNA (5′-GCTCAAGAAGTACTGACACAT-3′) were cloned in the pLKO.1 len-
tiviral vector. Briefly, 293 T cells (2 × 106) were seeded in 100 mm dish, one day before transfection in DMEM 
Thyroid Carcinoma cell lines
HTH83* CAL62** SW1736** OGK-M*** ATC351** C643** HTH7** HTH74** T238**
vWA 16,19 16 16,19 17 18 15,17 14,18 16,17 16,17
TPOX 8 8,9 11 8,9 8,11 11,12 11 8,10 8,11
TH01 6,9 7,9 6,9.3 6,10 7 9.3,10 9,9.3 8 7,9.3
D5S818 12 9,12 12,13 10,13 12,13 11,12 11 11,12 9,11
D13S317 11,13 12 11,12 10,12 11 8,10 11,14 12,13 12
D7S820 12 10 8,11 10,13 9,10 9,12 8,11 9 11,13
D16S539 11,12 12,13 11,12 9,12 9,11 9,13 9,13 9 11,12
CSF1PO 11 9,12 12 10,11 12 10,11 12 11,12 12, 13
AMEL XY X X XY XY XY X X X
Table 1. STR profiling of thyroid carcinoma cell lines. *STR profile by us matched to ATCC results. **STR 
profile by us matched to University of Kentucky (Lexington), University of Uppsala (Sweden), University of 
Colorado Cancer Centre and Memorial Sloan-Kettering Cancer Centre. ***STR profile matched to original 
profile (33).
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medium supplemented with 10% FBS for virus production. To generate lentivirus particle, 2 µg of (scrambled 
shRNA or XPO1 shRNA) vector was transfected along with 1.5 µg of pCMV-dr8.2 and 0.5 µg of pMD2.G in 293 T 
cells in 100 mm culture dish using lipofectamine transfection reagent streptomycin (Invitrogen, Carlsbad, CA). 
After 4 hours, the transfection medium was replaced with DMEM medium supplemented with 10% FBS. Cell cul-
ture supernatants containing the lentivirus were collected at 48 h and 72 h post-transfection and pooled. HTH83, 
OGKM, CAL62 and T238 cells (1 × 105 per well) were seeded in 6-well plate 24 h before transduction. Cells were 
transduced with lentiviral vectors at an MOI of 30 in the presence of 8 ug/ml polybrene (Sigma-Aldrich) for 24 h. 
Puromycin was used to eliminate uninfected cells, stable cells were selected using 1ug/ml puromycin for 2–3 
weeks.
Cellular proliferation assay. Cell growth was measured by colorimetric assays as described earlier16, 
47. Briefly, 20 ul, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) was 
added to each well of 96 well-plate and incubated at 37 °C for 2 h and then dissolved in 100 µl of stop solution 
(SDS-HCl). Absorbance was measured at 570 nm using a Tecan Infinite 200 PRO spectrophotometer (Mannedorf, 
Switzerland). Dose-response curves were plotted to obtained half-maximal inhibitory concentrations (IC50) for 
selinexor by GraphPad Software.
Colony formation assay. ATC cells (1 × 103) were seeded into 6-well plates in triplicates in complete 
medium. After two days, media were supplemented with varying concentration of selinexor. After 2 weeks, cells 
were fixed with 5% glutaraldehyde in PBS and stained with 0.1% crystal violet. Moreover, colonies were dissolved 
in 200 ul of DMSO and absorbance was measured at 570 nm Tecan Infinite 200 PRO spectrophotometer. Soft agar 
assay (anchorage-independent growth assay) was performed as described previousely47.
Annexin V and propidium iodide (Annexin V-PI) apoptosis analysis. Annexin V-PI staining was 
performed using flow cytometric analysis as previously described50. Briefly, 1 × 106 cells were cultured with 
increasing concentrations of selinexor (0–1000) for 24 h. Staining was performed using Apoptosis Detection 
Kit II (BD Biosciences, USA). Cells were harvested and washed twice with phosphate-buffered saline (PBS; Life 
technologies, USA). Cells were suspended in 1X binding buffer containing 5 ul of FITCI conjugated Annexin 
V and 5 ul of PI for 30 min in dark. The samples were analyzed using LSR-II flow cytometer (BD, San Jose, CA, 
USA).
Cell cycle analysis. To determine the effect of selinexor on cell cycle of ATC cells, cells were seeded at 50% 
confluency and after overnight incubation, culture media were replaced with fresh medium either diluent control 
or indicated concentrations of selinexor at indicated time points as described earlier50. Briefly, cells were washed 
with ice-cold PBS and fixed with 70% chilled ethanol. Cells were stained with PI solution (50 µg/ml PI, Triton 
X-100 (1%), 20 ug/ml DNase-free RNase A in PBS) for 30 min at 37 °C in the dark followed by flow cytometric 
analysis (BD, San Jose, CA, USA).
In vivo xenografts. The response of human ATC tumors to selinexor was examined using NSG mice as pre-
viously described47. Suspensions of 2 × 106 CAL62 cells mixed with matrigel (1:1) in 200 μl of total volume were 
injected subcutaneously into the right flank of 6-week male NSG mice. The mice were randomly divided into 
two groups (6 mice per group) to receive either vehicle (0.6% w/v aqueous Pluronic F-68) or selinexor (10 mg/
kg in 100 μl of the vehicle, 3 times per week). Tumor diameters were measured with a caliper, and tumor volumes 
were calculated by the formula (V = π/6 × Dl × Ds2)48, where V is volume, Dl is the largest diameter, and Ds is 
the smallest diameter. Mice were fed with Nutri-Cal (Tomlyn) thrice a week during treatment to provide good 
nutrition15. All mice were sacrificed at the end of the study. Tumors were dissected and weighed. One-half of 
each tumor was fixed in 10% formaldehyde for histological analysis, and the other half was immediately kept in 
−80 °C for subsequent RNA and protein analysis. We also analyzed peripheral blood for blood counts and serum 
chemistries after the 28-day treatment (Table 1). The animal studies were approved by the National University of 
Singapore (NUS) Institutional Animal Care and Use Committee (IACUC) and all the procedure were performed 
in accordance with the relevant guidelines and regulations.
Microarray and data analysis. Total RNA was isolated from three different clones in each group (groups: 
scrambled shRNA and LAMC2 shRNA) using the RNeasy mini kit (Qiagen, Valencia, CA) according to manufac-
turer’s protocol. RNA Nano chip on Agilent Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA) was 
used to check quality and quantity of RNA samples. cDNA and cRNA were synthesized using Illumina Total Prep 
RNA Amplification Kit (Illumina). Human gene HT-12 v4 Expression beads a chip kit (47,000 probes spotted 
genes) was from Illumina (Santa Clara, CA) were used.
Studies of drug combination. Results obtained from MTT assays for different combinations of selinexor 
and doxorubicin was evaluated by Calcusyn (Biosoft, UK). A combination index (CI) plot is a Fa-CI plot in which 
CI < 1, = 1, >1 indicate synergism, additive effect, and antagonism, respectively. Fa: the fraction that is inhibited 
by the drug.
Statistics Analysis. For in vitro and in vivo experiments, we evaluated the statistical significance of the dif-
ference between two groups using two-tailed Student t-test and two–way ANOVA. Asterisks in the figures rep-
resent significant differences between experimental groups in comparison to controls (*p < 0.01, **p < 0.001, 
***p < 0.0001). Data points in figures represent the means ± SD (standard deviation).
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